This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

Current Standards of Treatment in MS and the Role of Oral Agents

Harold Moses, Jr, MD

Published: July 15, 2014

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders


Multiple sclerosis (MS) is a devastating disease causing weakness, fatigue, cognitive problems, and other disabilities. Relapses cause significant functional impairment and decreased quality of life for patients with MS, and relapses are typically treated with short-term corticosteroids. Long-term treatment for relapsing MS consists of several types of disease-modifying therapies, most of which are administered by either IV or injection. While these therapies are effective, newer oral agents are now available. Although more long-term data are needed, oral agents may be more convenient and tolerable than injections or IVs and should be presented to patients as a potential therapy option.

Related Articles

Volume: 75

Quick Links: